ACS chemical neuroscience molecule spotlight on lorcaserin

Research output: Contribution to journalShort surveypeer-review

4 Scopus citations


Lorcaserin (APD-356) is the first in a new class of selective serotonin 5-hydroxytryptamine2C (5-HT2C) receptor agonists. On December 22, 2009, the compound's developer (Arena Pharmaceuticals) submitted an NDA to the FDA for approval for weight management.

Original languageEnglish (US)
Pages (from-to)718-719
Number of pages2
JournalACS Chemical Neuroscience
Issue number11
StatePublished - Nov 17 2010
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology


Dive into the research topics of 'ACS chemical neuroscience molecule spotlight on lorcaserin'. Together they form a unique fingerprint.

Cite this